Sign Out
No interaction studies have been performed (see Pharmacology: Pharmacokinetics: Biotransformation under Actions).
Concomitant use of Soolantra with other topical or systemic medicinal products for the treatment of rosacea has not been investigated.
In vitro studies have shown that ivermectin is primarily metabolised by CYP3A4. Consequently, caution is advised when ivermectin is administered concomitantly with potent CYP3A4 inhibitors as the plasma exposure may be significantly increased.
Continue with Google